NCT03527888View on ClinicalTrials.gov

Study of Anlotinib in Patients With Primary Malignant Bone Tumors

PHASE2UnknownINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 31, 2018

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions
Neoplasm of Bone
Interventions
DRUG

Anlotinib

Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent

Trial Locations (6)

100035

Beijing Jishuitan Hospital, Beijing

100142

Beijing Cancer Hospital, Beijing

200233

Shanghai No.6 People's Hospital, Shanghai

450008

Henan Cancer Hospital, Zhengzhou

610000

West China Hospital of Sichuan University, Chengdu

710032

The First Affiliated Hospital of the Air Force Medical University, Xi’an

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY